Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. The knowledge on the pathogenesis of AD is driving the development of new drugs. From the research results, it has been revealed that Th2 cell-mediated immunity, skin barrier dysfunction, and pruritus cause...
Main Authors: | Chisa Nakashima, Shigeto Yanagihara, Atsushi Otsuka |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Allergology International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893021001398 |
Similar Items
-
JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
by: Krzysztof Szalus, et al.
Published: (2020-11-01) -
Baricitinib for the treatment of atopic dermatitis
by: Amelia Melo, et al.
Published: (2022-07-01) -
A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
by: Sang-Doo Lee, MD, et al.
Published: (2022-12-01) -
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023-12-01) -
Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis
by: Daud Manzar, et al.
Published: (2024-03-01)